http://www.100md.com
王栋，陈锦华，武国军，王禾，吴卫真，杨顺良，林文洪
前列腺肿瘤；抗原,CD3；抗体亲和力；四聚体,,前列腺肿瘤；抗原，CD3；抗体亲和力；四聚体,0引言,1材料和方法,2结果,3讨论,【
Biological activity of tetramer of bispecific singlechain antibody against human prostatespecific antigen and CD3 molecule
WANG Dong, CHEN JinHua, WU GuoJun, WANG He, WU WeiZhen, YANG ShunLiang, LIN WenHong, TAN JianMing
Department of Urology, Statistic Room, Fuzhou General Hospital, Nanjing Military Area Commond, Fuzhou 350025, China, Department of Urology, Xijing Hospital, Fourth Military Medical University, Xian 710033, China
【Abstract】 AIM: To study the biological activity of tetramer of bispecific singlechain antibody against human prostatespecific antigen (PSA) and CD3 molecule. METHODS: Flow cytometry (FCM) was used to detect the binding activity of bispecific singlechain antibody to CD3positive cell line Jurkat and prostate carcinoma cell line LNCaP. The efficacy of the antibodiy in mediating tumor cell lysis in vitro was determined by using the 51Crrelease test. For in vivo evaluation of the antibodys activity, a nude mouse model was used. The mice were inoculated with LNCaP prostate cancer cells. RESULTS: It was demonstrated that the tetramer of bispecific singlechain antibody could bind to the Jurkat and LNCaP cells with high specificity. The percents of the cells bond by the antibody were 70.4% and 81%, respectively. In vitro, with activated CTLs as effector cells, a specific lysis of LNCaP cells mediated by the antibody was confirmed by 51Crrelease assay. The specific lysis rate of LNCaP cells was positively correlated to tBsAb concentration or effector / target cell ratio. The highest specific lysis rates were (80.3±5.2)% and (78.6±5.5)% in fixed antibody concentration group and fixed effector/target cell ratio group, respectively. In vivo, the antibody could suppress the tumor growth in nude mice significantly as compared to the group treated only with CTLs and the untreated control group (P<0.0001). CONCLUSION: The tetramer of bispecific singlechain antibody against human prostatespecific antigen and CD3 molecule has a good biological activity in binding antigens, mediating lysis of LNCaP cells and inhibiting tumor growth. ......
WANG Dong, CHEN JinHua, WU GuoJun, WANG He, WU WeiZhen, YANG ShunLiang, LIN WenHong, TAN JianMing
Department of Urology, Statistic Room, Fuzhou General Hospital, Nanjing Military Area Commond, Fuzhou 350025, China, Department of Urology, Xijing Hospital, Fourth Military Medical University, Xian 710033, China
【Abstract】 AIM: To study the biological activity of tetramer of bispecific singlechain antibody against human prostatespecific antigen (PSA) and CD3 molecule. METHODS: Flow cytometry (FCM) was used to detect the binding activity of bispecific singlechain antibody to CD3positive cell line Jurkat and prostate carcinoma cell line LNCaP. The efficacy of the antibodiy in mediating tumor cell lysis in vitro was determined by using the 51Crrelease test. For in vivo evaluation of the antibodys activity, a nude mouse model was used. The mice were inoculated with LNCaP prostate cancer cells. RESULTS: It was demonstrated that the tetramer of bispecific singlechain antibody could bind to the Jurkat and LNCaP cells with high specificity. The percents of the cells bond by the antibody were 70.4% and 81%, respectively. In vitro, with activated CTLs as effector cells, a specific lysis of LNCaP cells mediated by the antibody was confirmed by 51Crrelease assay. The specific lysis rate of LNCaP cells was positively correlated to tBsAb concentration or effector / target cell ratio. The highest specific lysis rates were (80.3±5.2)% and (78.6±5.5)% in fixed antibody concentration group and fixed effector/target cell ratio group, respectively. In vivo, the antibody could suppress the tumor growth in nude mice significantly as compared to the group treated only with CTLs and the untreated control group (P<0.0001). CONCLUSION: The tetramer of bispecific singlechain antibody against human prostatespecific antigen and CD3 molecule has a good biological activity in binding antigens, mediating lysis of LNCaP cells and inhibiting tumor growth. ......